This is a long-term, open-label extension study of bivamelagon in participants with Hypothalamic Obesity (HO) who have transitioned from the index study, LG-MCCL005. The study will last up to 2 years.
Thank you for your interest, but this study is recruiting by invitation only.
North Carolina (Statewide)
Elizabeth Harris
Medicine-Endocrinology
Clinical or Medical
Interventional
Obesity
25-2447